for the defect of tumor-bearing mice are not well understood, breaking the state of immunological unresponsiveness of tumor-bearing individuals to cancer is a prerequisite for active or passive immunotherapy. It is known that tumor cells can produce immunosuppressive substances or induce immune suppression . If this were important, then removing the tumor antigen from the tumor cell environment and presenting it on nonmalignant normal cells might induce an immunity specific for this antigen even in the tumor-bearing animal (TBA). ' To test this possibility, mice bearing progressively growing regressor or progressor tumors (RETBA or PROTBA) received transplants of either normal or malignant cells expressing the same highly immunogenic MHC class I antigen, designated K216 . We show that mice bearing the K`-negative progressor tumor (PROTBA) do not respond to highly immunogenic K"'-positive regressor tumor cells, but do respond to nonmalignant transgenic cells or tissue grafts expressing the same K216 antigen . Furthermore, mice bearing the progressively growing K111-positive regressor tumor (RETBA) also rejected K2"-positive skin, but this response had no measurable effect on the established tumor even though it expressed the same Kt arget antigen as the rejected skin.' These findings are consistent with the idea that immune responses may be induced in the TBA more effectively by presenting a tumor antigen on normal rather than malignant tissue but that such manipulation alone will not cause immunologic rejection of an established tumor.
Materials and Methods
Animals and Tumor Lines. C3H/HeN (MTV-), BALB/cAn, and C57BL/6 mice were obtained from the National Cancer Institute Frederick Animal Production Facility, Bethesda, MD. The skin tumor 1591-RE (9) was induced by UV irradiation and regresses when transplanted into normal C3H/HeN mice. Even though this tumor was reported to have originated in C3H/HeN (MTV -) (H-2k) mice (9) and expresses normal Kk and Dk MHC class I antigens, this tumor also expresses three immunogenic MHC class I antigens designated L9, D9, and K216 (10, 11) . The coding regions ofthe genes for the first two antigens are 100% homologous to L9 and D4 genes (11) . The third, K 216, does not represent K9 as determined by comparison of a partial DNA sequence of K4 made available to us by Dr. Gilbert Jay (National Cancer Institute, Bethesda, MD) ; the precise origin of the K 216 gene is still unknown, but it may well encode a normal alloantigen like the other two normal MHC class I genes found in the 1591-RE tumor. Gene K216 carries the number 216 because it was designated gene 216 when isolated from a genomic library of the 1591 regressor tumor (10) . It is designated as a K gene because this MHC class I gene contains the 27 extra base pairs (bp) in the intracytoplasmic domain characteristic for K genes. Furthermore, K216 lacks the L-and D-specific nucleotides in the leader sequence of exon I and is >99% homologous to Kk from a point 300 by 5' of exon 4 continuing 1,800 bases into the 3' untranslated region (12) . The K`6 gene encodes an antigen that alone is sufficient for tumor rejection by normal C3H/HeN mice (13) . This gene, along with the other two immunogenic class I antigens, D9 and L4 of the 1591-RE tumor, is always lost when 1591-PRO progressor variants of the tumor develop (13) . The 1591-PRO tumor (also designated 1591-PR04L or 1591VARS (13] ) used in this study is one of the progressor variants observed in 5 out of 100 animals that were challenged with fragments ofthe 1591-RE tumor (14) . 1591-PRO will grow progressively in -80% of normal mice after subcutaneous transplantation. This progressor variant when transfected with the K216 gene (designated K216 tumor) is always rejected by normal mice unless the K216 gene is lost (13) . 5128-PRO and 5117-RE are recently described UVinduced BALB/c tumors (15) . P815 is a mastocytoma that arose spontaneously in DBA/2 mice. All tumors were cultured in vitro in minimum essential medium containing 10% heat-inactivated FCS (CMEM) (14) .
Tansgenic Mice. The X phage clone K216 was restricted with Hind III and Sal I and the fragment containing the K216 gene was isolated from an agarose gel by electroelution. Approximately 200 copies were injected into the nuclei of C3H/HeN zygotes as previously described (16) . Founder mice and offspring were confirmed as containing the transgene by Southern blot analysis of DNA isolated from tails.
Southern Blotting. DNA was extracted from tumor cell lines grown in vitro or from tail cells ; DNA was digested to completion using an excess of restriction enzyme (New England Biolabs, Beverly, MA). The digested DNA was then separated on a 0.9% agarose gel and blotted onto Zetabind membrane (AMF Cuno, Meriden, CT) by capillary flow using 20 x SSC as transfer buffer. The conditions of the hybridization and the origin of the MHC class I-specific probe 149.6-6 have been described (10) .
Tumor Transplantation, Removal, and Readaptation to Culture. For tumor challenges, solid tumors grown in nude C3H mice that had been inoculated with cultured cells were implanted subcutaneously as 1-mm' fragments with a 13-gauge trocar. Deep anesthesia was induced by inhaled ethylether and chloral hydrate (240 mg/kg body weight) intraperitoneally. Fine needle biopsy aspirations ofthe tumors were done on anesthetized mice using a 10-ml syringe fitted with a 20-gauge, 1.5-inch needle. The plunger was withdrawn to the 9-ml mark to create maximal suction and two or three different locations of the tumor were sampled this way without withdrawing the needle tip from the initial insertion site in the tumor. The aspirates were expelled into CMEM containing gentamycin and cultured for a few days before analysis.
Transplantation ofNormal Tissues. Skin for grafting was obtained from the ventral surface of the donor mouse and applied to the dorsal thoracic wall according to an adaptation of the method of Billingham and Medawar (17) . Bandages were removed on day 7 and grafts were scored daily until rejection (defined as loss ofat least 80% of grafted tissue) or the end point ofthe experiment. Tissues for fetal gut or heart transplants were removed from 16-20-dold embryos. Fetal gut tissue was minced with a curved scissors into 1-2-mm3 sections, and three to four fragments of fetal gut or whole fetal heart were implanted through an incision 5 mm caudal to the base of the ear and moved close to the tip of the ear to allow easy inspection. Rejection or acceptance o£graft was confirmed histologically 3-5 wk after transplantation.
Induction of Cytolytic T Cells In Vivo and In Vitro. Polyurethane sponge matrix grafts (0.5 cm3; Future Foam Co., Chicago, IL) were transplanted as described (18) into anesthetized mice by passing the sponge graft through a subcutaneous tunnel and depositing it in the interscapular region. 5-10 x 106 stimulator cells were injected into the center of the sponges with a 25-gauge needle and at various times thereafter sponges were removed and placed into 5 ml ofcold RPMI 1640 containing 5 U ofheparin/ml. Cells to be used as effector cells in a "Cr-release assay were removed by squeezing the sponge with a forceps multiple times. In addition, a small fragment of the sponge was cultured to test for possible bacterial contamination of the removed implant . For the generation of cytolytic lymphocytes in vitro, tumorbearing or tumor-free mice were first immunized by injecting subcutaneous sponges or the peritoneal cavity with mitomycin C-treated or untreated tumor cells or spleen cells . At the time mice were killed, sponges were examined for absence of tumor growth since at the dose used tumors may occasionally grow out; however, no tumors have ever been observed in mice injected intraperitoneally with viable tumor cells . Spleen cells were restimulated in vitro in a mixed lymphocyte tumor cell culture (MLTC) as previously described (14) . Cytotoxicity was determined by the ability of effectors to lyse S'Cr-labeled target cells during a 6-h assay as previously described (14) . The percentage specific lysis was calculated by the formula: [(experimental release -spontaneous release)/(maximum release -spontaneous release)] x 100.
Thymocyte and DC Preparations. Thymocyte suspensions were prepared using the same methods as used for spleen cell preparations for an MLTC (13) . DC preparations were prepared as described (19) . Briefly, spleen cells were adhered to plastic culture dishes for 2 h and the nonadherent cells were removed by washing the plate three times with fresh medium .
The adherent macrophages and DC were incubated for an additional 22 h. DC detach during this second incubation so that the nonadherent cells recovered consist of N50-60% DC. For convenience, the cells in this preparation that contain NI to 2% of all nucleated cells present in a normal spleen are referred to as DC.
Flow Cytometric Analyses Cell Preparations. The antibody CP28, specific for the K216 gene, has been described (20) . The anti-MHC class I mAbs were gifts from Keiko Ozato (National Institutes of Health, Bethesda, MD) and their specificities have been described (21) 
Results
Generation of Transgenic Mice Expressing the K"6 MHC Class I Antigen. Transgenic mice were generated by microinjecting fertilized C3H/HeN oocytes with the Kus gene. DNA isolated from tails of the offspring was analyzed by Southern blotting. Fig . 1 A shows that two of seven animals contained a 950-bp polymorphic fragment characteristic of the K2" gene. To establish two independent K216 -transgenic lines of mice, these two male founder mice were mated to normal C3H/HeN female mice. performed to test the immune response of normal C3H/HeN mice to K 216 transgenic tissues . As can be seen in Table 1 , normal C3H/HeN mice rejected K216_ transgenic skin after the same time interval as they rejected fully MHC 1-disparate allogeneic skin grafts. A possible trivial explanation for the highly effective rejection of the transgenic skin by normal mice might be that expression of additional antigens had been induced by insertional mutagenesis and that the rejection of the K216-transgenic skin was not specific for the K216 antigen . However, Table I also shows that the independent lineages of K216 _transgenic mice derived from two different microinjected oocytes accepted skin grafts exchanged between them suggesting that no additional, artificially generated antigens contributed to the efficient rejection. In addition, polyurethane sponges placed under the skin of normal mice and injected with K216 _transgenic spleen cells led to the generation of sponge-infiltrating lymphocytes that lysed the K2" -transfected tumor cells but not untransfected progressor tumor cells . Also, spleen cells from these K2 "-immunized mice gave rise in culture to CTL that specifically killed the K2" -positive tumor cells when restimulated in vitro with the K216 _transgenic spleen cells (data not shown). Together, these experiments suggest that normal C3H/HeN mice rejected the transgenic grafts with the same efficiency as fully allogeneic skin grafts in a K 216 -specific way.
Mice Bearing a Prog gressor Tumor Do Not Reject a K216 positive Tumor but Do Reject Nonmalignant Grafts Expressing the Same Antigen. Table II shows that mice bearing an established 1591-PRO tumor (K 216 -negative) fail to reject K 216 -positive 1591 regressor tumors or 1591-PRO tumors transfected with the K216 MHC class I gene (encoding the antigen for tumor rejection) . An important finding, shown in Table II , is that even though the progressor tumor-bearing mice failed to reject K216 -positive tumors, these PROTBA's regularly rejected K216 _transgenic skin grafts as rapidly as they rejected allogeneic skin grafts . Both types of grafts were rejected by the PROTBA with only a slight delay of 1-2 d as compared with the time required for normal tumor-free mice.
It is conceivable that differences between the proliferative state ofthe normal and malignant tissues were responsible for the differences between the response oftumorbearing mice to K 21 '-positive skin versus K216 _positive tumors, thus favoring tumor outgrowth. However, Table II shows that these TBA rejected allogeneic tumors that rapidly proliferated and formed tumors before they were rejected. Furthermore, these TBA also rejected K 211 -positive fetal gut transplants from K 216 -transgenic mice . These fetal gut transplants showed histologically high mitotic activity and formed tumor-like masses of 3-10 mm in diameter in syngeneic transgenic controls. Thus, differences in the proliferative state of the transplanted tissue cannot account for the different responses of TBAs to transplanted normal and malignant tissues.
Progressor Tumor-bearing Mice Generate K216 _specic CTL in Response to the Antigen on Normal But Not on Malignant Cells. Since progressor tumor-bearing mice accepted K216 -positive tumors but rejected K 2 "-positive skin grafts, we explored whether these differences correlated with differences in the cytolytic T cell response to the K216 antigen on normal or malignant cells. K 216 -transfected tumor cells or K216_ 15 . Fig. 2 gives an example of the differences observed 15 d after injection of malignant or normal stimulator cells. Spleen cells of these TBA were then restimulated in vitro with K2t6 _transgenic spleen cells or the K216 -transfected mitomycin C-treated tumor cells. Fig. 3 shows that cultures ofspleen cells from progressor tumorbearing mice responded with K2"-specific CTL when the cells had been stimulated by K2t6 _transgenic spleen cells (A-D), but not when stimulated with the K2t6-positive tumor cells in vivo and in vitro (E-G). K216 -positive tumor cells, however, effectively stimulated the in vitro generation of K 2t6 _specific CTL from spleen cells of tumor-free K216 -immune mice (Fig. 4) . K"6 Regressor Tumor-bearing Mice Which Reject K2`Skin Nevertheless Do Not Select for Antigen Loss Variants. We have shown previously that the K"'-negative progressor tumor grows at about an 80% incidence when transplanted into tumor-free mice (14) . If the K216 antigen is the only antigen that causes the change from progressor to regressor phenotype, then the K"'-positive and the K216 -negative tumors should grow at about the same 80% tumor incidence in K216 transgenic mice, and this appears to be the case, Table III .
We have shown previously (6) that K216 -positive regressor tumors injected into progressor tumor-bearing mice grow progressively, even if the progressor tumor is subsequently removed (9 d or longer after challenge with the regressor).4 Though the tumor grows as an antigen-positive tumor in these mice (7), nevertheless the mice rejected K216 -positive transgenic skin (Table III) Progressor tumor fragments were first injected into the right flank of mice. After 4-5 wk of growth, fragments of the K216 -transfected tumor were implanted subcutaneously in the contralateral left flank. 10-14 d after challenge with the K216 _positive regressor tumor, the progressor tumor was excised. 5-7 d after removal of the progressor tumor the mice received a transplant of K216 -positive skin . These mice rejected K 216 skin but more slowly than normal recipients . The delay did not seem to correlate directly with the size of the regressor tumor nor to the duration of tumor engraftment (data not shown) ; nor was the delay specific for the K2`a ntigen since rejection of allografts was similarly delayed (Table III) . Nevertheless, all of the by flow cytometry for expression of the K216 antigen (Fig. 5) . In only one animal did the tumor show partial but significant K2" antigen loss after rejection of the K216 -positive skin graft. From previous experiments, we know that K 216 antigen loss occurs before the K216 -transfected tumors can grow in immunocompetent mice (13) and that K 216 antigen expression is not lost after prolonged growth ofthese tumors in T cell-deficient hosts such as nude mice or progressor TBA (8) . We do not have sufficient concurrent controls to suggest that this observation of partial loss in one of the tumors was due to induction of immunity to the K2" antigen by the skin graft. Even if this was so, it is very striking that all the other K" tumor-bearing mice failed to show any evidence of immunoselection in the progressively growing K 216 tumors, despite the fact that all of these tumor-bearing mice generated sufficient K 216 -specific immunity to reject skin grafts expressing the same Three reasons that are commonly proposed to explain the failure of the immune system to destroy established tumors : (a) lack of a strong rejection antigen, (b) release of large amounts of tumor antigen causinghost immune cells to become refractory, and (c) rapid proliferation of tumor cells that outstrips the capacity of the immune system to respond effectively. Our experiments suggest that none of these three mechanisms are very important in the present model.
The target antigen clearly had the strong antigenicity of an MHC class I alloan- T cells, then these mice should not have been able to reject the K216 -positive transgenic skin grafts . Though the rejection of K216 -positive skin was delayed in the K`T BA, these mice showed a similar delay of rejection of antigenically unrelated allogeneic skin grafts, which is consistent with the apparent absence of antigen specificity of the suppression in the TBA (7) . If the proliferative capacity of the tumor was simply greater than the killing capacity of the immune response generated, then anti-K 216 immunity caused by K216 -positive skin rejection should have caused some slowdown in K216 tumor growth . Alternatively, at least some evidence for immune selection for K216 loss variants should have been found after weeks of continued tumor growth in the nominally immune mice . Selection for variants readily occurs in the absence of a detectable effect on tumor size in short-term UV irradiated mice (22) or in X-irradiated, thymectomized, spleen cell-reconstituted mice with partially compromised but still demonstrable tumor antigen-specific immunity (8) . Thus, selection for antigen loss variants appears to be a particularly sensitive measure of antitumor immunity. The observed absence of selection seen here strongly suggests the absence of any antigen-specific tumor cell destruction in the tumor, and it is therefore unlikely that the tumor simply grew because it outstripped the killing capacity of the immune system . Certainly, differences in the mitotic activity of the transplanted tissues seem not to be sufficient to explain why TBA reject transgenic skin, since TBA also rejected K216 -positive fetal gut transplants that display a very high mi- totic index. Together, our experiments fail to support the notion that low antigenicity, large antigen load, or inadequate proliferative capacity of the immune cells (as compared with the tumor) were responsible for the failure of the anti-K 216 immunity to be effective. At present, we do not know why TBA fail to reject the K216 tumors when these animals rejected nonmalignant tissue transplants expressing the same target antigen. Kaliss (23) noted many years ago that it was considerably easier to enhance tumor allografts than normal tissue allografts with alloantisera and he suggested that the ability of tumors to be enhanced more easily "characterizes a fundamental difference between cancerous and normal tissues." Possibly grafts of normal tissues are rejected consistently because they contain Langerhans cells, which are absent in tumors but which can powerfully stimulate allogeneic responses (24) . Even though the tumor-free host can reject regressor tumors despite an absence of Langerhans cells or dendritic cells, antigen presentation by such cells may be important for the rejection by host with enhanced allografts . For example, injection of dendritic cells can abruptly terminate long-term allograft enhancement (25, 26) . Although dendritic cells pulsed with lyophilized tumor antigen failed to induce tumor rejection (27) it is not known whether dendritic cells transfected to express tumor-specific antigens can lead to rejection of an established cancer.
Local factors at the tumor site may prevent immune cells from entering and rejecting tumor grafts, and the nature and specificity of tumor infiltrating lymphocytes need to be determined . Malignant cells are metabolically very active and can produce substances that may be immunosuppressive by inhibiting leukocyte attraction, antigen presentation, or effector function of T cells. Such substances produced at the site of the established tumor may act as a local barrier to infiltration by tumorspecific lymphocytes and/or prevent immune destruction . Such substances could reduce systemic immune reactivity, and the fact that TBA showed delayed allogeneic skin rejection is consistent with some degree of systemic immune suppression. In previous studies, we have shown that mice bearing UVinduced tumors have suppressor lymphocytes that can prevent the tumor rejection of regressor tumors by normal host lymphocytes upon adoptive transfer (7, 8) . Such suppresser cells induced by malignant tissues might possibly lead to local intratumor suppression; however, the specificity and function of these suppressor cells that are absent from athymic tumor-bearing mice remains to be determined .
There are some interesting parallels between allograft and tumor enhancement. Pregnant individuals reject paternal skin allografts without aborting (28, 29) , and rats harboring long-term enhanced renal allografts reject donor type skin without rejecting the renal transplants (30) . In both instances, the survival time of the skin graft is slightly prolonged, similar to that observed for K216 -positive skirt grafts in the mice carrying K216 -positive tumors . While some of the parallels between the different systems are striking, none of the systems have resolved the precise mechanisms for: (a) the enhancement of the primary graft, (6) the slight prolongation of the secondary graft, and (c) the failure of immune cells that must participate in rejecting the second graft to affect the survival of the first graft. Possibly the tumor escapes through a loophole in the immune defense that had to be left open because allogeneic fetuses must not be rejected by the pregnant mother. Thus, if we can un-derstand why the mother fails to reject her fetus we may learn why an individual fails to respond to immunogenic tumors.
Whatever the mechanism(s) underlying our observations, it appears that responses can be induced in the TBA by presenting the "tumor" antigen on nonmalignant rather than malignant tissues . A potentially powerful approach to be used in the future may be the genetic transfer ofthe expression of a tumor antigen into nontumor cells, particularly into cells that have potent immunostimulatory activity, such as dendritic cells (31) . Although induction oftumor-specific immune responses in the tumorbearing host may be essential for tumor rejection, additional therapeutic manipulations may be required to cause immunological rejection of established tumors.
Summary
Breaking the state of immunological unresponsiveness of tumor-bearing individuals to cancer is a prerequisite for active or passive tumor-specific immunotherapy. To study this problem the immunogenic MHC class I antigen, K216 was transfected into a progressor tumor . The transfected tumors were regularly rejected by normal mice but grew progressively in mice bearing nontransfected tumors. In addition, transgenic mice were derived to obtain normal cells and tissues expressing the same -positive tissue grafts, but this in vivo response failed to lead to rejection of the simultaneously present tumor graft expressing the same antigen ; in fact, immunity had no measurable effect whatsoever on tumor size or incidence and caused no selection for antigen loss variants. Taken together, the present findings suggest that transfer of expression of a target antigen into nonmalignant cells provides a way for obtaining effective stimulation ofantigenspecific CTL in tumor-bearing mice, but that additional manipulations will be required to cause immunological rejection of established tumors.
